← SGLT2 inhibitors × cardiovascular events

SynthesisFrontiers in endocrinology2022

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.

Xuefeng Li et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2022

Randomised comparison

Probably reduced cardiovascular events

−28%−41% to −12%

Bigger than 6 in 10 for cardiovascular events

As reported

HR 0.72, 95% CI 0.59–0.88

Randomised comparison

Probably reduced cardiovascular events

−20%−33% to −3%

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.80, 95% CI 0.67–0.97

Randomised comparison

Probably reduced cardiovascular events

−36%−52% to −14%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.64, 95% CI 0.48–0.86

Randomised comparison

Probably reduced cardiovascular events

−34%−50% to −13%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.66, 95% CI 0.50–0.87

+1 more in the walkthrough ↓

Five numbers in the abstract

the abstract, start to end

Sotagliflozin (HR 0.72 95%CI 0.59-0.88, SUCAR=0.93) and canagliflozin (HR 0.80 95%CI 0.67-0.97, SUCAR=0.73) …

Canagliflozin (HR 0.64 95%CI 0.48-0.86, SUCAR=0.73), sotagliflozin (HR 0.66 95%CI 0.50-0.87, SUCAR=0.69) and empagliflozin (HR 0.65 95%CI 0.43-0.98, SUCAR=0.68) …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.720.59–0.88
Cardiovascular events
HR 0.800.67–0.97
Cardiovascular events
HR 0.640.48–0.86
Cardiovascular events
HR 0.660.50–0.87
Cardiovascular events
HR 0.650.43–0.98
SGLT2 inhibitorsCardiovascular events

SGLT2 inhibitors × cardiovascular eventshelps?mixed

unlikelylikely
0.50not counted
← favours comparatorfavours treatment →
more certainless certain
1 / 5

6 papers cite it

2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 36589800